CPPG

Pricing Availability   Qty
说明: Potent group III mGlu antagonist
化学名: (RS)-α-Cyclopropyl-4-phosphonophenylglycine
纯度: ≥98% (HPLC)
说明书
引用文献 (21)
评论 (2)
文献 (3)

生物活性 for CPPG

CPPG is a potent group II/III mGlu receptor antagonist, with approximately 20-fold selectivity for group III over group II (IC50 values of 2.2 and 46.2 nM respectively). A much less potent antagonist at group I receptors in neonatal rat cortical slices (KB = 0.65 ± 0.07 nM).

技术数据 for CPPG

分子量 271.21
公式 C11H14NO5P
储存 Store at RT
纯度 ≥98% (HPLC)
CAS Number 183364-82-1
PubChem ID 2878
InChI Key IGODGTDUQSMDQU-UHFFFAOYSA-N
Smiles NC(C2CC2)(C(O)=O)C1=CC=C(P(O)(O)=O)C=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for CPPG

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
1eq. NaOH 27.12 100

制备储备液 for CPPG

以下数据基于产品分子量 271.21。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 3.69 mL 18.44 mL 36.87 mL
5 mM 0.74 mL 3.69 mL 7.37 mL
10 mM 0.37 mL 1.84 mL 3.69 mL
50 mM 0.07 mL 0.37 mL 0.74 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for CPPG

分析证书/产品说明书
选择另一批次:

参考文献 for CPPG

参考文献是支持产品生物活性的出版物。

Jane et al (1996) Potent antagonists at the L-AP4- and (1S, 3S)-ACPD-sensitive presynaptic metabotropic glutamate receptors in the neonatal rat spinal cord. Neuropharmacology 35 1029 PMID: 9121605

Toms et al (1996) The effects of (RS)-α-cyclopropyl-4-phosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. BrJ.Pharmacol. 119 851 PMID: 8922731

Kemp et al (1996) α-Methyl-3-phosphonophenylglycine and α-cyclopropyl-4-phosphonophenylglycine are potent antagonists at mGluRs negatively coupled to adenylyl cyclase. Br.J.Pharmacol. 117 (in press)


If you know of a relevant reference for CPPG, please let us know.

关键词: CPPG, CPPG supplier, potent, group, III, Antagonists, Group, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGlu4R, mGlu6R, mGlu7R, mGlu8R, Glutamate, Metabotropic, (Metabotropic), 0972, Tocris Bioscience

21 篇 CPPG 的引用文献

引用文献是使用了 Tocris 产品的出版物。 CPPG 的部分引用包括:

Nieus et al (2014) Regulation of output spike patterns by phasic inhibition in cerebellar granule cells. Front Cell Neurosci 8 246 PMID: 25202237

Ali (2011) CB1 modulation of temporally distinct synaptic facilitation among local circuit interneurons mediated by N-type calcium channels in CA1. J Neurophysiol 105 1051 PMID: 21123660

Bennett et al (2014) Examination of VLC-PUFA-deficient photoreceptor terminals. J Neurosci 55 4063 PMID: 24764063

Domin et al (2014) Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo. Proc Natl Acad Sci U S A 26 99 PMID: 24402869

De-May and Ali (2013) Cell type-specific regulation of inhibition via cannabinoid type 1 receptors in rat neocortex. J Neurophysiol 109 216 PMID: 23054605

Dornier (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat Commun 8 2255 PMID: 29269878

Balakrishnan et al (2009) Slow glycinergic transmission mediated by transmitter pooling. Nat Neurosci 12 286 PMID: 19198604

Spampinato et al (2015) Glial metabotropic glutamate receptor-4 increases maturation and survival of oligodendrocytes. Neurotox Res 8 462 PMID: 25642169

Ichinose and Lukasiewicz (2012) The mode of retinal presynaptic inhibition switches with light intensity. J Neurosci 32 4360 PMID: 22457487

He et al (2012) Increased Kv1 channel expression may contribute to decreased sIPSC frequency following chronic inhibition of NR2B-containing NMDAR. Neuropsychopharmacology 37 1338 PMID: 22218089

Broadstock et al (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165 1034 PMID: 21627638

Cassé et al (2012) Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 32 5186 PMID: 22496564

Tassin et al (2016) Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network. Front Neural Circuits 10 31 PMID: 27199672

Zhang et al (2010) RGS7 and -11 complexes accelerate the ON-bipolar cell light response. Invest Ophthalmol Vis Sci 51 1121 PMID: 19797214

Hellmer et al (2018) A group I metabotropic glutamate receptor controls synaptic gain between rods and rod bipolar cells in the mouse retina. Physiol Rep 6 e13885 PMID: 30338673

Jiang et al (2006) Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on DArgic neurons through a microtubule-dependent mechanism. J Neurosci 26 4318 PMID: 16624952

Newman (2005) Calcium increases in retinal glial cells evoked by light-induced neuronal activity. Front Cell Neurosci 25 5502 PMID: 15944378

Rancillac et al (2006) Glutamatergic Control of Microvascular Tone by Distinct GABA Neurons in the Cerebellum. J Neurosci 26 6997 PMID: 16807329

Mathiesen et al (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138 1026 PMID: 12684257

Nishi et al (2003) Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Invest Ophthalmol Vis Sci 100 1322 PMID: 12538871

Collard et al (2002) Neutrophil-derived glutamate regulates vascular endothelial barrier function. J Biol Chem 277 14801 PMID: 11847215


您是否知道使用了 Tocris CPPG 的优秀论文? 请告知我们.

CPPG 的评论

平均评分: 5 (基于 2 条评论。)

5 星
100%
4 星
0%
3 星
0%
2 星
0%
1 星
0%

Have you used CPPG?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Used in inhibitor cocktail.
By Anonymous on 12/03/2019
分析类型: In Vitro
种属: Rat
细胞系/组织: Retinal rod bipolar cells

Retinal dissections were performed in HEPES-buffered extracellular solution containing glutamate inhibitor cocktail - 600 umol/L

PMID: 30338673
review image

Use of CPPG as a blocker of mGluRs group III.
By Anonymous on 09/17/2019
分析类型: In Vitro
种属: Rat
细胞系/组织: Cerebellum

CPPG (5 microM) was used for pharmacological isolation of GABA-A receptor activity in nucleated membrane patches. Being added to perfusion solution, CPPG blocked contaminating receptor activity in a recorded response, thus revealing clear GABA-ergic single-channel openings. Figure: single-channel openings of GABA-A receptors in a membrane patch after application of CPPG.

Compound should be sonicated when dissolving.

PMID: 30042389
review image

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.